Sophia Antipolis, France - Galderma's commitment to dermatology, and dermatology only, is nowhere more evident than in its sprawling, approximately 24,000-square-foot research and development facility in the south of France.
Derm In The News: September 22-28
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations